Sector: Health Care
Director information for ADAPTIVE BIOTECHNOLOGIES CORP (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Chad Robins | Chief Executive Officer and Chairman | 51 | [] | [] | 2026 |
| Harlan Robins, PhD | Chief Scientific Officer | 53 | [] | [] | 2026 |
| Katey Owen, PhD | Director | ["Therapeutics / drug discovery: R&D expertise","Director level position in pharmaceutical development","overall extensive scientific expertise and strategic insights into commercialization and manufacturing at scale","PhD","Member"] | [] | 2026 | |
| Michelle Griffin | Director | ["Compliance and risk management","therapeutics / drug discovery: commercialization expertise","finance","Director of life sciences companies","audit committee chair experience","CEO/CFO experience","overall extensive operational experience in the biotechnology industry","deep experience in public company financial matters","MBA","Chair of Audit Committee"] | ["Audit Committee"] | 2026 | |
| Peter Neupert | Director | ["Diagnostic and pharmaceutical services: commercial expertise","capital growth","finance (funding)","Director of diagnostic laboratory services provider","venture capital provider experience","overall extensive experience in executive leadership roles in the health services sector","member of the board of directors of several organizations in the biotechnology industry","MBA"] | [] | 2026 | |
| Peter Neupert(1) | ["Member","Chair of Nominating and Corporate Governance Committee"] | ["Audit Committee","Compensation and Human Capital Committee","Nominating and Corporate Governance Committee"] | 2026 | ||
| Robert Hershberg, PhD, MD | Director | ["Therapeutics / drug discovery: extensive R&D and commercialization expertise","CEO positions in the biotechnology industry","deep technical expertise","overall extensive executive leadership experience in the biotechnology industry","operational experience managing sustained revenue and commercial growth in a strategic manner","PhD/MD","Chair of Compensation and Human Capital Committee","Member"] | ["Compensation and Human Capital Committee"] | 2026 | |
| Sharon Benzeno, PhD | Chief Commercial Officer, Immune Medicine | 52 | [] | [] | 2026 |
